The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial
Authors
Keywords
Everolimus, Cyclophosphamide, mRCC, Tregs, mTOR, Immune monitoring
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-01-17
DOI
10.1007/s00262-018-2288-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
- (2018) Charlotte M. Huijts et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions
- (2018) Aly-Khan A. Lalani et al. EUROPEAN UROLOGY
- Immunological effects of everolimus in patients with metastatic renal cell cancer
- (2017) Charlotte M Huijts et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
- (2016) Holger Moch et al. EUROPEAN UROLOGY
- FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
- (2016) MASARU KATOH INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma
- (2016) Robert J Motzer et al. LANCET ONCOLOGY
- Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
- (2016) Alena Gros et al. NATURE MEDICINE
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
- (2015) Bin Shang et al. Scientific Reports
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer
- (2013) Claudia C. Preston et al. PLoS One
- Substantially Modified Ratios of Effector to Regulatory T Cells During Chemotherapy in Ovarian Cancer Patients Return to Pre-Treatment Levels at Completion: Implications for Immunotherapy
- (2012) Anthony Park et al. Cancers
- Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
- (2011) Charlotte M Huijts et al. BMC CANCER
- CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes
- (2011) Fangfang Liu et al. BREAST CANCER RESEARCH AND TREATMENT
- Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
- (2011) Yingzi Ge et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma
- (2008) Jin F. Li et al. BJU INTERNATIONAL
- Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival
- (2008) H. van Cruijsen et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search